ArticleBiotechnology letters2026
Recombinant basic fibroblast growth factor produced in Nicotiana benthamiana enhances cell viability and wound healing.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Basic Fibroblast Growth Factor (bFGF), also known as FGF2, is a multifunctional growth factor involved in several physiological and pathological processes, including angiogenesis, wound healing, and embryonic development. This study aimed to investigate the feasibility and efficacy of producing recombinant bFGF in Nicotiana benthamiana using a geminiviral transient expression vector. The primary objective was to assess the bioactivity of N. benthamiana-produced bFGF in comparison with commercially available recombinant bFGF preparations produced in different heterologous expression systems. NIH-3T3 cells were exposed to varying concentrations (0.5-1000 ng/mL) of plant-produced bFGF for 24 and 48 h. The assessment parameters included cell viability, cellular responses, and wound-healing capacity. The plant-produced bFGF exhibited slightly greater cell viability compared to the non-treated control and a modest increase in cell proliferation. The analysis of the dose-response curve yielded an EC50 value of 0.171 ng/mL highlighting the bioactivity and potency of plant-produced bFGF. These results demonstrate the efficacy of plant-derived bFGF in promoting cellular activities and facilitating wound closure, underscoring its potential for wound healing applications. However, further validation through preclinical and clinical studies is warranted.
Indexed as
Identifiers
42467389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.